Christopher Bernard, Chris Emery
Curetis announced that Christopher Bernard has resigned as CEO and president of Curetis USA, as well as from the firm's management board, effective Aug. 31. The company has appointed Chris Emery to replace him, effective Sept. 1.
Bernard joined Curetis USA as CEO and president in July 2016 and had served on Curetis NV's management board since June 2018.
Emery has more than 20 years of commercial experience in the diagnostic and pharmaceutical industries. Prior to Curetis, Emery served as chief commercial officer of North America for Menarini Silicon Biosystems, where he directed US sales and business development activities for the DepArray Nxt molecular device and integrated the CellSearch Circulating Tumor Cell test. He has also served as general manager for Abbott's PersonalizeDx cancer diagnostics laboratory division and has held senior level management roles at CombiMatrix, Response Genetics, and US Labs.
Becton Dickinson has elected Jeffrey Henderson to its board of directors. Henderson is the non-executive chairman of the board of Qualcomm, serves on the boards of FibroGen and Halozyme Therapeutics, and is an advisory director to Berkshire Partners. He previously served as CFO of Cardinal Health for nearly 10 years and has also held positions at Eli Lilly and General Motors.
HTG Molecular Diagnostics has appointed Michelle Griffin to its board of directors. Griffin currently serves as a board member and chair of the audit committee for Acer Therapeutics. She has previously served as a board member and as audit committee chair for multiple firms since 2016, including PhaseRx, OncoGenex Pharmaceuticals, and Sonus Pharmaceuticals. In addition, Griffin has served in executive roles at OncoGenex, Trubion Pharmaceuticals, Dendreon, and Corixa over the past two decades.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.